Compare AbCellera Biologics Inc (ABCL) vs Howmet Aerospace Inc (HWM) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Howmet Aerospace (HWM) trades at $277.91, up 2.77% today, reflecting strong momentum in the aerospace and defense sectors. The stock exhibits bullish technical signals with support at $273 and resistance at $282. Recent earnings show mixed results, with Q1 2026 missing estimates, but robust profitability metrics like a 20.22% net margin and 33.98% ROE highlight operational strength. Positive sentiment is driven by defense demand and commercial aerospace growth, as noted in Zacks Investment Research articles from July 2026.

Outlook remains positive with an 83% analyst buy rating and a $313.50 consensus price target, suggesting 13% upside. Risks include premium valuations (P/E of 62.74) and execution challenges amid economic uncertainty. The company's cash flow growth and dividend payments support investor confidence, but high multiples warrant caution for new entries.